46 completed, 11 terminated, 5 unknown, 2 active not recruiting. 40 Phase 1, 25 Phase 2, 8 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Stage IV Mantle Cell Lymphoma: new trials by email Literature Review of Stage IV Mantle Cell Lymphoma trials Research Report on Stage IV Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma CD19.CAR-T cells - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2015-12-01 | 2019-02-27 |
| Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma ibrutinib, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | Northwestern University | 37 | 2015-01-12 | 2026-06-10 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Unknown | Chinese PLA General Hospital | 12 | 2013-04-01 | 2016-01-28 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine - Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma | Phase 2 | Completed | Roswell Park Cancer Institute | 37 | 2011-12-06 | 2024-02-07 |
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 23 | 2011-10-03 | 2023-07-27 |
| Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma bortezomib, filgrastim, autologous hematopoietic stem cell transplantation - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 23 | 2011-07-01 | 2021-05-10 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
Showing 20 of 66. Sign in to see all of them.
Lymphoma, Mantle-Cell (66) · Lymphoma, Follicular (61) · Lymphoma, Large B-Cell, Diffuse (59) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Lymphoma, B-Cell, Marginal Zone (53) · Burkitt Lymphoma (51) · Lymphoma, Non-Hodgkin (51) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Lymphoma, Large-Cell, Immunoblastic (48) · Hodgkin Disease (42) · Waldenstrom Macroglobulinemia (38) · Lymphoma, T-Cell, Cutaneous (36) · Mycosis Fungoides (35) · Sezary Syndrome (35) · Lymphoma, Large-Cell, Anaplastic (30)
Hemic and Lymphatic Diseases (66) · Immune System Diseases (66) · Immunoproliferative Disorders (66) · Lymphatic Diseases (66) · Lymphoproliferative Disorders (66) · Neoplasms (66) · Neoplasms by Histologic Type (66) · Lymphoma (65) · Lymphoma, B-Cell (61) · Disease Attributes (59) · Hematologic Diseases (59) · Leukemia, Lymphoid (59) · Pathologic Processes (59) · Pathological Conditions, Signs and Symptoms (59) · Chronic Disease (58)
Rituximab (11) · fludarabine phosphate (10) · Cyclophosphamide (9) · Peripheral Blood Stem Cell Transplantation (9) · Mycophenolic Acid (8) · Whole-Body Irradiation (8) · Bortezomib (6) · Cyclosporine (5) · Tacrolimus (5) · Etoposide (4) · Filgrastim (4) · Granulocyte Colony-Stimulating Factor (4) · Therapeutics (4) · Vorinostat (4) · tanespimycin (4)
National Cancer Institute (NCI) (28) · Fred Hutchinson Cancer Center (10) · Chinese PLA General Hospital (4) · City of Hope Medical Center (4) · Roswell Park Cancer Institute (3) · Case Comprehensive Cancer Center (2) · Northwestern University (2) · AIDS Malignancy Consortium (1) · Amir Mortazavi (1) · Barbara Ann Karmanos Cancer Institute (1) · Burzynski Research Institute (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Martin, Paul (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Chicago (1)
United States (58) · China (6) · Italy (3) · Canada (2) · Germany (2) · Denmark (1)
Brenda Sandmaier (3) · Patricia LoRusso (2) · Paul Martin (2) · Ramesh Ramanathan (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1) · Antonius Miller (1) · Barbara Pro, MD (1) · Bo Zhu, M.D., Ph.D. (1) · Brad Kahl (1) · Brian Hill, MD (1)
PMID 32499241, PMID 34515338, PMID 18698002, PMID 19900571, PMID 24458437, PMID 25085357, PMID 25317870, PMID 25444722, PMID 25964296, PMID 26451310, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28817727, PMID 29263894, PMID 29599530, PMID 29954415, PMID 30562587, PMID 31076448, PMID 31388792, PMID 31815579, PMID 32245502, PMID 32628342, PMID 33420905, PMID 33492438, PMID 35157306, PMID 36282798, PMID 37756532, PMID 40720747, PMID 41804087
P30CA015704 (5), U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), P01CA018029 (4), U01CA062502 (3), U01CA062505 (3), U01CA076576 (3), P30CA022453 (2), U01CA069852 (2), U01CA069912 (2), U01CA132123 (2), N01CM62208 (1), P01CA078902 (1), P30CA014520 (1)